|
Capricor Therapeutics inc (NASDAQ: CAPR) |
|
Capricor Therapeutics inc
CAPR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Capricor Therapeutics Inc 's sales fell
by -63.44 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 181
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.76 %
Capricor Therapeutics Inc net loss increased from $-6 millions, to $-13 millions in III. Quarter 2024,
• More on CAPR's Growth
|
|
Capricor Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 8 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 20.46.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.41.
• More on CAPR's Valuation
|
|
|
|
|
Capricor Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 8 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 20.46.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.41.
Capricor Therapeutics Inc Price to Book Ratio is at 6.96 lower than Industry Avg. of 91.79. and higher than S&P 500 Avg. of 0.01
• More on CAPR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com